Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy
By: Gianfranco A Pesce , Alessandro Clivio , Luca Cozzi , Giorgia Nicolini , Antonella Richetti , Emanuela Salati , Mariacarla Valli , Eugenio Vanetti and Antonella Fogliata

Radiation Oncology 2010, 5:54 doi:10.1186/1748-717X-5-54
Published: 16 June 2010

Abstract (Provisional)

Background

To report about initial clinical experience in radiation treatment of carcinoma of prostate with volumetric modulated arcs with the RapidArc (RA) technology.

Methods

Forty-five patients with a median age of 72+/-3, affected by prostate carcinoma (T1c: 22 patients, T2a-b: 17 patients, T3a-b: 6 patients. N0: 43 patients, N1-Nx: 2 patients, all M0), with initial PSA of 10.0+/-3.0 ng/mL, were treated with RapidArc in a feasibility study. All patients were treated with single arc using 6MV photons. Dose prescription ranged between 76 (7 patients) and 78 Gy (38 patients) in 2Gy/fraction. Plan quality was assessed by means of Dose Volume Histogram (DVH) analysis. Technical parameters of arcs and pre-treatment quality assurance results (Gamma Agreement Index, GAI) are reported to describe delivery features. Early toxicity was scored (according to the Common Terminology Criteria of Adverse Effects scale, CTCAE, scale) at the end of treatment together with biochemical outcome (PSA).

Results

From DVH data, target coverage was fulfilling planning objectives: V95% was in average higher than 98% and V107%~0.0% (D2%~104.0% in average). Homogeneity D5%-D95% ranged between 6.2+/-1.0% to 6.7+/-1.3%. For rectum, all planning objectives were largely met (e.g. V70Gy=10.7+/-5.5% against an objective of <25%) similarly for bladder (e.g. D2%=79.4+/-1.2Gy against an objective of 80.0Gy). Maximum dose to femurs was D2%=36.7+/-5.4Gy against an objective of 47Gy. Monitor Units resulted: MU/Gy=239+/-37. Average beam on time was 1.24+/-0.0 minutes. Pre-treatment GAI resulted in 98.1+/-1.1%. Clinical data were recorded as PSA at 6 weeks after RT, with median values of 0.4+/-0.4 ng/mL. Concerning acute toxicity, no patient showed grade 2-3 rectal toxicity; 5/42 (12%) patients experienced grade 2 dysuria; 18/41 (44%) patients preserved complete or partial erectile function.

Conclusion

RapidArc proved to be a safe, qualitative and advantageous treatment modality for prostate cancer.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production






* Albert Einstein College of Medicine has been
awarded Acceditation with Commendation by
the ACCME

Copyright 2025 InterMDnet | Privacy Policy | Disclaimer | System Requirements